These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20443719)

  • 1. Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy.
    Tuomikoski P; Mikkola TS; Tikkanen MJ; Ylikorkala O
    Climacteric; 2010 Oct; 13(5):457-66. PubMed ID: 20443719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical markers for cardiovascular disease in recently postmenopausal women with or without hot flashes.
    Tuomikoski P; Mikkola TS; Hämäläinen E; Tikkanen MJ; Turpeinen U; Ylikorkala O
    Menopause; 2010; 17(1):145-51. PubMed ID: 19602991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy.
    Tuomikoski P; Haapalahti P; Sarna S; Ylikorkala O; Mikkola TS
    Ann Med; 2010 Jul; 42(5):334-43. PubMed ID: 20429800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex hormone-binding globulin and serum testosterone are inversely associated with C-reactive protein levels in postmenopausal women at high risk for cardiovascular disease.
    Joffe HV; Ridker PM; Manson JE; Cook NR; Buring JE; Rexrode KM
    Ann Epidemiol; 2006 Feb; 16(2):105-12. PubMed ID: 16216530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasomotor hot flashes and heart rate variability: a placebo-controlled trial of postmenopausal hormone therapy.
    Lantto H; Haapalahti P; Tuomikoski P; Viitasalo M; Väänänen H; Sovijärvi AR; Ylikorkala O; Mikkola TS
    Menopause; 2012 Jan; 19(1):82-8. PubMed ID: 21934534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of hot flushes on cardiovascular autonomic responsiveness: a randomized controlled trial on hormone therapy.
    Hautamäki H; Haapalahti P; Piirilä P; Tuomikoski P; Sovijärvi A; Ylikorkala O; Mikkola TS
    Maturitas; 2012 Jul; 72(3):243-8. PubMed ID: 22537767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
    Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
    Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1mg estradiol valerate/2mg dienogest on hot flushes in postmenopausal women.
    Endrikat J; Graeser T; Mellinger U; Ertan K; Holz C
    Maturitas; 2007 Oct; 58(2):201-7. PubMed ID: 17889463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
    Mattsson LA; Skouby S; Rees M; Heikkinen J; Kudela M; Stadnicki-Kolendo A; Mattila L; Salminen K; Vuorela A; Mustonen M;
    Menopause Int; 2007 Sep; 13(3):124-31. PubMed ID: 17785038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application.
    Mueck AO; Genazzani AR; Samsioe G; Vukovic-Wysocki I; Seeger H
    Menopause; 2007; 14(6):978-84. PubMed ID: 17595593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Menopausal hot flushes do not associate with changes in heart rate variability in controlled testing: a randomized trial on hormone therapy.
    Hautamäki H; Mikkola TS; Sovijärvi AR; Piirilä P; Haapalahti P
    Acta Obstet Gynecol Scand; 2013 Aug; 92(8):902-8. PubMed ID: 23656530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy?
    Shulman LP
    J Fam Pract; 2004 Jul; Suppl():S13-7. PubMed ID: 15251108
    [No Abstract]   [Full Text] [Related]  

  • 16. Short-term results of transdermal estrogen replacement therapy in cardiovascular disease-free postmenopausal females with and without hypertension.
    Modena MG; Rossi R; Muia N; Origliani G; Rombolà O; Molinari R
    G Ital Cardiol; 1998 Jun; 28(6):636-44. PubMed ID: 9672776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study.
    Stevenson JC; Durand G; Kahler E; Pertyński T
    Maturitas; 2010 Nov; 67(3):227-32. PubMed ID: 20688442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone replacement therapy in postmenopausal women.
    Yasui T; Uemura H; Takikawa M; Irahara M
    J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article.
    Lakoski SG; Herrington DM
    Climacteric; 2005 Dec; 8(4):317-26. PubMed ID: 16390766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response.
    Silvestri A; Gebara O; Vitale C; Wajngarten M; Leonardo F; Ramires JA; Fini M; Mercuro G; Rosano GM
    Circulation; 2003 Jul; 107(25):3165-9. PubMed ID: 12796135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.